In addition to the aforementioned strategies, a few studies have examined the synergistic effects of IL‐24 with TRAIL adenovirus (Zhao et al. 2006), anti‐VEGF ribozyme adenovirus (Chang et al. 2009), and OSM adenovirus (Xu et al. 2014) in various in vitro and in vivo cancer models, demonstrating promising therapeutic outcomes. The gene discussed is VEGFA; the disease is cancer.